CALGARY, AB / ACCESSWIRE / December 3, 2021 / Marvel Biosciences (TSXV:MRVL), and its wholly owned subsidiary, Marvel Biotechnology Inc., today announced that it will be presenting at the SNN Network Canada Virtual Event 2021 on Wednesday, December 8th at 2:00 PM EST. President and CSO Mark Williams will be hosting the presentation and answering questions from investors.

To access the live presentation, please use the following information:

SNN Network Canada Virtual Event 2021
Date: Wednesday, December 8, 2021
Time: 2:00 PM Eastern Time (11:00 AM Pacific Time)
Webcast: https://www.webcaster4.com/Webcast/Page/2813/43699

If you would like to book 1on1 investor meetings with Marvel, and to watch the company's presentation, please make sure you are registered for the virtual event here: https://canada.snn.network/signup

1on1 meetings will be scheduled and conducted via private, secure video conference through the conference event platform.

The SNN Network Canada Virtual Event website is available here: https://canada.snn.network/

If you can't make the live presentation, all company presentations "webcasts" will be available directly on the conference event platform on this link under the tab "Agenda": https://canada.snn.network/agenda

News Compliments of Accesswire

About Marvel Biosciences Corp.

Marvel Biosciences Corp., and its wholly owned subsidiary, Marvel Biotechnology Inc., is a Calgary-based pre-clinical stage pharmaceutical development biotechnology company that utilizes a "drug redevelopment" approach to drug development. Historically, when a new class of drug is developed, it is optimized for a particular target, but typically only approved for a specific disease. Often, a new disease is identified which involves the same target, however, pending the remaining patent life, the originally approved drug may not have sufficient time left for it to be commercially viable to be developed for the new disease indication. Marvel develops new synthetic chemical derivatives of the original approved drug for the new disease indication. Patent protection is sought as the new potential asset is developed by the Company. The Company believes the business model results in significantly less risk, cost and time to develop its assets compared to traditional biotechnology companies.

Marvel Biotechnology Inc. has currently developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs, that inhibit the A2a adenosine receptor with application to neurological diseases (depression & anxiety, Alzheimer's, ADHD), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis ("NASH"). Marvel is also exploring additional undisclosed targets to expand its asset pipeline.

About SNN.Network

SNN.Network is your multimedia financial news platform for discovery, transparency and due diligence. This is your one-stop hub to find new investment ideas, check in on watchlist, gather the most up-to-date information on the Small-, Micro-, Nano-Cap market with the goal to help you towards achieving your wealth generation goals. Follow the companies YOU want to know more about; read and watch content from YOUR favorite finance and investing influencers; create YOUR own watchlist and screen for ideas YOU'RE interested in; find out about investor conferences YOU want to attend - all here on SNN Network.

If you would like to attend the SNN Network Summer Virtual Event 2021, please register here: https://conference.snn.network/signup

For further information please contact:
Investor Relations:
Virtus Advisory Group
Tel: 416-644-5081
Email: info@virtusadvisory.com

Marvel Biosciences Corp.
J. Roderick (Rod) Matheson, Chief Executive Officer or
Dr. Mark Williams, President and Chief Science Officer
Tel: 403 770 2469
Email: info@marvelbiosciences.com

SOURCE: Marvel Biosciences via SNN Network